Direct Measurement of CD4+ and CD8+ T-Cell Responses to CMV in HIV-1-Infected Subjects  by Komanduri, Krishna V. et al.
m
C
t
c
m
r
W
i
r
c
i
r
e
1
t
t
B
n
a
F
g
Virology 279, 459–470 (2001)
doi:10.1006/viro.2000.0697, available online at http://www.idealibrary.com onDirect Measurement of CD41 and CD81 T-Cell Responses to CMV in HIV-1-Infected Subjects
Krishna V. Komanduri,*,1 Sean M. Donahoe,† Walter J. Moretto,† Diane K. Schmidt,* Geraldine Gillespie,‡
Graham S. Ogg,† Mario Roederer,¶ Douglas F. Nixon,†,2 and Joseph M. McCune*,¶,3
*Gladstone Institute of Virology and Immunology, P.O. Box 419100, San Francisco, California 94141-9100; †Aaron Diamond AIDS Research Center,
The Rockefeller University, 455 First Avenue, New York, New York, 10016; ‡MRC Human Immunology Unit, Institute of Molecular Medicine, Oxford
OX3 9DS, United Kingdom; §Vaccine Research Center, National Institutes of Health, 40 Convent Drive, Bethesda, Maryland 20892; and
¶Departments of Medicine and Microbiology and Immunology, University of California at San Francisco, San Francisco, California 94143
Received May 23, 2000; returned to author for revision August 25, 2000; accepted October 3, 2000
Data from murine models of chronic viral infection suggest that CD41 T-cell responses to viral pathogens are important
in sustaining the number and/or function of CD81 cytotoxic T-cell (CTL) effectors. In this study, we used cytokine flow
cytometry (CFC), staining with HLA-A*0201-peptide tetramers, and peptide stimulation with epitopic peptides to study
functional CD41 and CD81 T-cell responses to cytomegalovirus (CMV) in human subjects coinfected with CMV and the
human immunodeficiency virus, type 1 (HIV-1). We show that strong CD41 and CD81 T-cell responses to CMV antigens are
sustained over time in HIV-1-infected individuals. Those who maintain a strong CD41 T-cell response to CMV are also likely
to maintain higher frequencies of CD81 T cells capable of binding to HLA-A*0201-CMV pp65 (A2-pp65) tetramers as well
as responses to pp65 peptide stimulation with effector cytokine production. These data support the hypothesis that declines
in frequencies of CD41 T-cell responses to CMV are associated with an inability to sustain high levels of CMV-specific CD81
T-cell responses in HIV-1-infected subjects. These declines may precede the onset of CMV-associated end organ disease.
© 2001 Academic Press
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1The cytotoxic T-cell response to viral pathogens is
arked by four phases: (1) activation and expansion of
D81 antigen-specific clones; (2) reduction of viral load
hrough effector mechanisms, including cytolysis; (3)
ontraction, by apoptosis, of effector populations; and (4)
aintenance of long-lived antigen-specific memory (for
eviews, see Ahmed and Gray, 1996 and Kalams and
alker, 1998). The role of antigen-specific CD41 T cells
n the initiation and maintenance of these CD81 CTL
esponses has been evaluated in murine models of
hronic viral infection (e.g., with lymphocytic choriomen-
ngitis virus or murine herpesviruses). A protective CTL
esponse can be mounted through the initial phase of
xpansion (Rahemtulla et al., 1991; von Herrath et al.,
996) without the need for CD41 T-cell help; thereafter,
he number and/or function of CTLs may not be sus-
ained and control of viral replication may be impaired if
1 Present address: M. D. Anderson Cancer Center, Department of
lood and Marrow Transplantation, Section of Transplantation Immu-
ology, 1515 Holcombe Blvd., Houston, TX 77030.
2 Present address: Gladstone Institute of Virology and Immunology,
P. O. Box 419100, San Francisco, CA 94141-9100.
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t Gladstone Institute of Virology and Immunology, P. O. Box 419100, Sana
o
rancisco, CA 94141-9100. Fax: (415) 826-8449. E-mail: mmccune@
ladstone.ucsf.edu.
459D41 T-cell help is absent (Battegay et al., 1994; Cardin
t al., 1996; Matloubian et al., 1994; Zajac et al., 1998).
Our understanding of T-cell responses during chronic
viral infections has been greatly facilitated by the recent
introduction of sensitive and specific methods to enu-
merate and to characterize the function of CD41 and
CD81 T cells. Direct flow cytometric visualization of
CTLs using tetrameric complexes consisting of HLA
class I, b2-microglobulin, and epitopic peptide (reviewed
n Ogg and McMichael, 1998) revealed that T cells re-
ponding to a single antigen may expand dramatically
e.g., to frequencies of .40% of peripheral CD81 T cells)
n the setting of experimental murine infections (Murali-
rishna et al., 1998) and during acute human Epstein–
arr virus infection (Callan et al., 1998). In individuals
nfected with HIV-1, the frequency of CD81 T cells spe-
ific for immunodominant HLA-A*0201-restricted Gag
nd Pol epitopes (detected using HIV-1-specific tetra-
ers) was found to be inversely correlated with plasma
IV-1 viral load, implicating HIV-1-specific CTL in the
ontrol of viral replication and disease progression (Ogg
t al., 1998). Flow cytometric methods have also enabled
he characterization of antigen-specific CD41 T-cell sub-
ets, detecting specific responses to CMV and HIV-1 by
ntracellular detection of cytokines after antigen stimula-
ion (Pitcher et al., 1999; Waldrop et al., 1997). Using suchcytokine flow cytometry (CFC) assay for CMV, we dem-
nstrated that CMV-specific CD41 T-cell responses
0042-6822/01 $35.00
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460 KOMANDURI ET AL.were diminished in HIV-1-infected subjects who had
CMV end organ disease (EOD) but preserved in HIV-1-
infected subjects without a history of such EOD (Koman-
duri et al., 1998). In other studies using a CFC assay for
HIV-1 (Pitcher et al., 1999), HIV-specific CD41 T-cell
responses were preserved in subjects treated soon after
infection with HIV-1 but were undetectable in the majority
of subjects after prolonged (.47 weeks) suppression of
viremia.
To better define the interdependence of CD41 and
CD81 T-cell responses to chronic viral infections in
human subjects, we used antigen-specific MHC tetra-
mers and the CFC assay to assess CMV-specific T-cell
responses in subjects infected with both CMV and HIV-1.
Our results show that the magnitude of CMV-specific
CD41 T-cell responses is positively associated with the
frequency of CMV-specific CD81 T cells in HIV-1-in-
fected subjects, confirming predictions derived from mu-
rine models of chronic viral infection.
RESULTS
Flow cytometric quantitation of CD41 and CD81 T-
cell responses to CMV
Figure 1 shows T-cell responses to CMV detected in
the peripheral blood of an HIV-1-infected, CMV-seropos-
itive (HLA-A*02011) subject (Patient 4 in Table 1). To
quantitate functional CD41 T-cell responses to CMV,
freshly isolated PBMC were stimulated either with a
CMV lysate (Fig. 1A, left) or with a matched control
antigen (Fig. 1B, right). As previously described (Koman-
duri et al., 1998), the frequency of CMV-specific cells was
determined by gating on the fraction of CD41 T cells
expressing the cell surface activation marker CD69 and
intracellular TNFa. To determine whether CD81 T cells
pecific for CMV were present in the peripheral blood of
his patient, cells were stained with PE-conjugated HLA
2-pp65 tetramers (Fig. 1B). The fraction of CD31CD81
cells specific for this immunodominant CMV epitope
5.3%) was determined by quantitating tetramer-binding
ells by flow cytometry. By contrast, few (0.03%)
D31CD81 T cells in the peripheral blood of this patient
ound to an HLA-A*0201-restricted HIV-1 Gag epitope.
D81 T cells responsive to the CMV pp65 epitope were
lso enumerated after direct stimulation in the CFC as-
ay: 2.3% of CD81 T cells were found to upregulate
D69 and produce intracellular TNFa after stimulation
with this peptide. As expected, activation of CD41 T
cells was minimal under these conditions (e.g., 0.10% in
Fig. 1C, right).
These data confirm previous observations (Komanduri
et al., 1998; Pitcher et al., 1999; Waldrop et al., 1997) that
flow cytometry may be used to identify responsive CD41
T cells and that CMV-specific CD41 T cells are present
in very high frequencies in some HIV-1-infected individ-
uals. Additionally, MHC tetramer staining reveals high
t
0frequencies of CD81 T cells specific for the immuno-
dominant CMV pp65 antigen in a subset of HIV-1-in-
fected individuals. Since CD81 T cells within these pa-
tients can also respond to stimulation with the CMV pp65
peptide, it is likely that the tetramer-binding subpopula-
tion contains functional effector cells.
Stability of antigen-specific CD41 and CD81 T-cell
responses
To study the maintenance of antigen-specific CD41
T-cell responses within individuals over time, we pro-
spectively analyzed the peripheral blood CD41 CMV-
specific CFC responses of 12 HIV-1-infected CMV-sero-
positive subjects over a period of approximately 1 year.
Ten of 12 subjects had received HAART for greater than
1 year at the initiation of observation; two had initiated
HAART less than 6 months prior to the first assessment.
The frequency of CMV-specific CD41 T cells by CFC
was determined for each subject (Fig. 2A). Overall,
CD41 T-cell responses to CMV were very stable, without
significant variation over time (median slope 5 20.002%/
day; range 20.012 to 10.009%/day).
The stability of CD81 T-cell responses were evaluated
for one HLA-A*02011 individual for whom banked PBMC
ere available for several time points over a 450-day
eriod of follow-up. Consistent with the results for other
ubjects, this subject’s CD41 responses measured by
he CFC assay (Fig. 2B) were stable following stimulation
y staphylococcal enterotoxin B (means 6 SD 5 29.53 6
1.83%) or by CMV (21.55 6 3.81%). Similarly, the frequency
of CD81 T cells specific for CMV remained stable, mea-
sured either using HLA A2-pp65 tetramers (5.23 6 0.64%)
or after stimulation in the CFC assay with the CMV pp65
peptide (2.64 6 0.32%). These data indicate that even
HIV-1-infected individuals can maintain high and stable
frequencies of CMV-specific CD41 and CD81 T cells.
Association between functional CMV-specific CD41
T-cell responses and CD81 T-cell responses to CMV
pp65 antigen
To better define the association between CD41 and
CD81 T-cell responses to CMV in HIV-1-infected sub-
jects, we identified a group of 21 HLA-A*02011 individ-
als who were coinfected with HIV-1 and CMV, and who
id not have a prior history of CMV-associated EOD.
MV serostatus, HLA typing, and T-cell counts (e.g.,
otal, CD41 and CD81 T-cell counts/ml) were obtained
or each individual (Table 1). Functional CD41 T-cell
esponses in the peripheral blood of these individuals
ere determined using the CMV-CFC assay; specific
D81 T-cell responses were visualized using HLA A2-
p65 tetramers. CD41 CMV-specific frequencies ranged
rom 0.6 to 46% (means 5 5.86%), while HLA A2-pp65
etramer-specific CD81 T-cell frequencies ranged from
.04 to 5.13% (means 5 1.23%). Paired CD41 and CD81
461CD41/CD81 T-CELL RESPONSES TO CMV IN HIV-1 INFECTIONFIG. 1. Quantitation of CMV- and HIV-1-specific CD41 and CD81 T-cell responses in an HLA-A*02011 individual coinfected with HIV-1 and CMV.
(A) CMV-specific CD41 T-cell responses are shown for an HIV-1- and CMV-coinfected individual. PBMC were stimulated with lysates of CMV antigens
(left panel) or a matched control antigen (right panel) in the presence of antibody to CD28 and brefeldin A. Following stimulation, cells were fixed,
permeabilized, and stained with monoclonal antibodies specific for CD4 (conjugated to FITC), CD69 (conjugated to PerCP), and TNFa (conjugated
to PE). The frequency of cells responsive to CMV or the control antigen was determined by the fraction of CD41 cells which upregulated CD69 and
expressed detectable amounts of intracellular TNFa (upper right quadrants). (B) CD81 T-cell responses to CMV and to HIV-1 measured by tetramer
staining. PBMC were stained with antibody to CD8 (conjugated to tricolor) and with a PE-conjugated HLA A2-tetramer containing either the CMV pp65
NLVPMVATV epitope (left panel) or the HIV-1 Gag SLYNTVATL epitope (right panel). (C) CD81 functional responses to CMV measured by peptide
stimulation and intracellular cytokine staining. PBMC were stimulated with the CMV pp65 NLVPMVATV peptide in the presence of antibody to CD28
and brefeldin A. The frequency of cells functionally responsive to CMV was determined by flow cytometry, with responsive cells determined by double
staining with antibodies specific for CD69 (conjugated to PerCP) and for TNFa (conjugated to PE) within lymphocyte populations demarcated by
staining with antibodies specific for CD8 (conjugated with FITC, left panel) or CD4 (conjugated with APC, right panel).
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462 KOMANDURI ET AL.CMV-specific responses (analyzed by CFC and by tet-
ramer staining, respectively) are shown in Fig. 3A.
To examine the quantitative relationship of CD41 T-cell
esponses to CD81 T-cell responses, we stratified the 21
LA-A*02011 subjects into quartiles based on percentile rank
see Materials and Methods). Using these quartiles as a basis
or comparison, we then examined the relationship between
D81 CMV-specific T-cell responses and CD41 CMV-spe-
ific responses in the HLA-A*02011 individuals. Individuals
ith the lowest (Quartile 1) CD41 T-cell responses by CFC
ad significantly lower frequencies (Fig. 3B) and total numbers
FIG. 2. Longitudinal stability of T-cell responses to CMV in HIV-1-in
CMV-associated end organ disease were enrolled in a prospective stud
to CMV are shown for 12 HIV-1-infected subjects. CD41 T-cell respon
at least four times over an approximately 1-year period. Each poin
compartment (in %) that were CD691 TNFa1 following CMV stimula
atched control antigen. (B) Longitudinal CD41 and CD81 T-cell respo
D81 T-cell responses to CMV were determined by CFC or by HLA
taphylococcal enterotoxin B (SEB, closed black diamonds) or to CMV
ith SEB or CMV by the CFC assay. Each point represents the frequenc
f .15 months. The frequency of CD81 T cells specific for the immu
LVPMVATV tetramer and expressed as a fraction (in %) of CD81 T cells
by CFC assay) was determined following stimulation of PBMC with the
fraction (in %) of CD81 T cells. CD81 T-cell responses (by tetramerf cells (after adjustment with the total CD81 T-cell count) (Fig.
C) capable of binding to the A2-pp65 tetramer relative tothose with the highest (Quartile 4) responses (P 5 0.009 in
each case). Reciprocally, increasing CD41 CMV-specific re-
sponses (grouped in Quartiles 2–4) were associated with a
higher frequency and total number of CD81 CMV-specific
cells as measured by A2-pp65 tetramer staining.
Association between CMV pp65 tetramer-binding and
the magnitude of functional responses to CMV pp65
peptide stimulation in CD81 T-cells
To determine whether the HLA A2-pp65 tetramer-bind-
ubjects. HIV-1-infected, CMV-seropositive subjects with no history of
igen-specific immune function. (A) Longitudinal CD41 T-cell responses
CMV were determined by CFC in 12 subjects examined prospectively
circles) represents the frequency of cells within the CD41 T-cell
D41 CMV-specific frequencies were adjusted by stimulation with a
ere evaluated for one HLA-A*02011 HIV-1-infected subject. CD41 and
65 tetramer staining. The frequency of CD41 T cells responsive to
diamonds) was determined after stimulation of freshly isolated PBMC
V-specific CD41 T cells (as defined above) during a follow-up period
nant pp65 antigen was determined by staining with an HLA A2-pp65
circles). The frequency of CD81 T cells capable of functional response
ic pp65 NLVPMVATV peptide (closed black circles) and expressed as
g and CFC assay) were determined from banked, thawed PBMC.fected s
y of ant
ses to
t (open
tion. C
nses w
A2-pp
(open
y of CM
nodomi
(opening cells were capable of functional responses, PBMC
obtained from 21 HLA-A*02011 HIV-1-infected, CMV-
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463CD41/CD81 T-CELL RESPONSES TO CMV IN HIV-1 INFECTIONseropositive subjects were stimulated with the pp65 pep-
tide and analyzed for CD81 T-cell responses using the
CFC assay. A strong positive correlation was observed
between the frequency of HLA A2-pp65 tetramer-binding
cells and of CD691 TNFa1 CD81 T cells, which re-
sponded to pp65 peptide stimulation (R 2 5 0.85, P 5
.001, Fig. 3B). Notably, the absolute number of CD81 T
ells that was functionally reactive in the HLA A2-pp65
FC assay was always less than the number of CMV
p65 tetramer-binding cells, raising the possibility that
ome of the CD81 tetramer-binding cells in these indi-
iduals may be nonresponsive (as measured by CD69
pregulation and TNF production). The ratio of peptide-
esponsive cells by CFC to A2-pp65 tetramer-binding
ells was similar from subject to subject and averaged
5% overall (slope of regression 5 0.55, Fig. 4A).
ssociation between CD41 functional responses to
MV and CD81 functional responses to CMV pp65
eptide stimulation
TABLE 1
Characteristics of CMV-Seropositive HIV-1-Infected Subjects
Patient HLA A2
CD41 count
(cells/ml)
CD81 count
(cells/ml)
HIV-1 viral load
(log10 copies/ml)
1 1 210 3108 1.3
2 1 275 1103 3.1
3 1 284 1002 4.0
4 1 479 2359 ,1.7
5 1 670 869 ,1.7
6 1 442 1685 ,1.7
7 1 753 2145 ,1.7
8 1 112 440 4.5
9 1 438 1067 2.1
10 1 466 1088 ,2.7
11 1 680 1523 ,1.7
12 1 908 1805 ,1.7
13 1 1357 798 ,1.7
14 1 976 1006 4.15
15 1 478 700 ,1.7
16 1 370 1109 1.86
17 1 853 771 ,1.7
18 1 1147 1246 2.22
19 1 726 955 ,1.7
20 1 441 1584 ,1.7
21 1 523 314 ,1.7
Note. Clinical characteristics, including CD41 and CD81 T-cell
ounts and HIV-1 viral load, were determined in a hospital clinical
aboratory for all subjects. All subjects were analyzed by CD41 CFC
ssay (following stimulation with CMV and control antigens), by CD81
etramer staining (using the HLA A2-pp65 NLVPMVATV and HLA A2-
ag SLYNTVATL tetramers), and for functional CD81 T-cell response to
MV (by the CFC assay following stimulation with the CMV pp65
LVPMVATV peptide). HIV-1 plasma viral loads were determined either
y HIV-1 bDNA measurement or by reverse transcriptase-polymer
hain reaction in a cinical laboratory.We next determined the relationship between the fre-
uency of CMV-specific CD41 T cells responsive in the
a
tFC assay and the frequency of CD81 T cells respond-
ng to the CMV pp65 peptide. CD41 functional re-
ponses to CMV were studied in 21 HLA-A*02011 sub-
ects and compared to CD81 T-cell responses elicited
fter stimulation with the pp65 peptide. The pp65 CD81
FC responses were again stratified by CD41 response
uartiles, as described above. Subjects with the lowest
D41 CMV-specific T-cell responses (Quartile 1) had
ignificantly lower total numbers of CD81 pp65-respon-
ive cells by CFC than those in Quartiles 2–4 (P 5 0.04,
ig. 4B). A trend toward significance was also observed
P 5 0.08, data not shown) when frequencies of CD81
p65-stimulated CFC responses (fraction of CD81 cells)
ere similarly stratified based on CD41 CMV-specific
esponses.
ubjects with low CD41 CMV-specific responses
ave lower total CD81, but not CD41, T-cell counts
To determine whether deficiencies in CD41 antigen-
pecific T-cell responses were associated with trends in
verall CD41 or CD81 T-cell counts, we compared total
-cell counts in groups stratified by their CD41 CMV-
pecific T-cell response measured by CFC. No statisti-
ally significant differences were observed in total CD41
-cell counts between groups stratified by CD41 T-cell
esponses (Fig. 5A, P . 0.6 for all quartile comparisons).
hen total CD81 T-cell counts were similarly compared,
roups of subjects with higher CD41 CMV-specific T-cell
esponses had higher total CD81 T-cell counts (Fig. 5B,
uartile 1 vs 3, P 5 0.04, Quartile 1 vs 4, P 5 0.009,
uartile 3 vs 4, P 5 0.03).
DISCUSSION
Most HIV-1-infected subjects are also coinfected with
MV, a human gammaherpesvirus that remains a major
ause of morbidity and mortality in immunocompromised
ubjects (e.g., in AIDS and in the setting of myeloablative
hemotherapy) (Cunningham and Margolis, 1998; Ljung-
an, 1998). The study of CD41 and CD81 T-cell re-
ponses to CMV in HIV-1-infected subjects offers an
pportunity to extend previous studies in animal models
f chronic persistent viral infection (e.g., LCMV), exam-
ning the relationship between CD41 and CD81 T-cell
esponses to viral pathogens. Until recently, it was diffi-
ult to enumerate the frequencies of CD41 or CD81 T
ells responding to viral pathogens in human subjects.
he development of HLA-peptide tetramers to study
D81 T-cell responses (McHeyzer-Williams et al., 1996;
gg and McMichael, 1998) and cytokine flow cytometry-
ased methods to quantitate CD41 antigen-specific T
ells (Picker et al., 1995; Waldrop et al., 1997) led to a
eevaluation of the precursor frequencies of CD41 and
D81 T cells arising in the setting of viral infection (Butz
nd Bevan, 1998; Murali-Krishna et al., 1998). In addition
o these two methods, the responses of human CD81 T
464 KOMANDURI ET AL.
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465CD41/CD81 T-CELL RESPONSES TO CMV IN HIV-1 INFECTIONcells may be quantitated by flow cytometry following
stimulation with epitopic peptides (Kern et al., 1998). In
this study, we utilized these methods to study CD41 and
CD81 T-cell responses to CMV in 21 HLA-A*02011
HIV-1-infected subjects.
Previous studies (Waldrop et al., 1997; Komanduri et
l., 1998) demonstrated that the CMV-specific CD41
-cell response to HIV-infected individuals is dominated
y TH1 polarization. This response consists primarily of
ells that produce both TNFa and IFNg, with strong
orrelations between CMV-specific T-cell frequencies
erived via measurement of TNFa and IFNg production
Komanduri et al. unpublished results). It was also pre-
iously established that most CMV-specific CD81 T cells
n HIV-1-infected subjects (identified by HLA A2-pp65
etramer staining) produce both TNFa and IFNg follow-
ng epitopic peptide stimulation (Appay et al., 2000). For
his reason, we confined our analyses of CMV-specific
-cell frequencies to those determined using intracellular
NFa production as an endpoint.
We first confirmed the observation (Komanduri et al.,
998; Pitcher et al., 1999; Waldrop et al., 1997) that CMV-
pecific CD41 T cells are present in high frequencies in
IV-1-infected subjects. The magnitude and stability of
MV-specific CD41 T-cell responses were examined
ver a period of 12 months in 12 HIV-1-infected subjects
eceiving highly active antiretroviral therapy. CD41 T-cell
esponses following stimulation with CMV remained sta-
le during this interval in all subjects, with only a slight
edian decline (median slope 5 20.002%/day) noted
verall for CD41 CMV-specific responses. In one HLA-
*02011 subject analyzed longitudinally for CD41 and
D81 CMV-specific T-cell responses, similar stability
as also observed in the proportion of CD81 T cells
esponsive to CMV measured both by HLA A2-pp65
etramer staining and by the CMV pp65 CFC assay. A
ecent cross-sectional study suggested that some HIV-
-infected subjects maintained on prolonged (.47
eeks) antiretroviral therapy have reduced frequencies
but unchanged absolute counts/ml) of CD41 T cells
responding to CMV relative to untreated subjects
(Pitcher et al., 1999). These data suggest that long-term
suppression of HIV-1 is not always associated with loss
of T-cell responses against other viral pathogens or im-
FIG. 3. Association of CD41 and CD81 T-cell responses to CMV in
HIV-1-infected subjects. Responses for all 21 HLA-A*02011 subjects s
in individual subjects. (B) Individuals with low CD41 T-cell responses t
by tetramer staining. CD41 T-cell responses to CMV (by the CFC assa
The quartile bounds were as follows: Quartile 1 ,1.47%; Quartile 2 $ 1
T-cell responses to CMV pp65 (determined by staining with the HLA
quartile rank based on responses to CMV in the CD41 T-cell comp
tetramer-binding cells (in %). (C) The association of CD41 CMV-speci
capable of binding the A2-pp65 tetramer (adjusted for the total CD81 T
by the Mann–Whitney U test (One subject was studied by A2-pp65 tetramer s
all other subjects were done at coincident time points.)mediate normalization of skewing in the repertoire in
subjects with high frequency T-cell responses to viruses
such as CMV.
Substantial evidence from animal models supports the
hypothesis that CD41 T cells are important in sustaining
the CTL effector response in the setting of chronic viral
infection (reviewed in Kalams and Walker, 1998). These
data predict that a similar association between the
CD41 and CD81 T-cell response might be observed in
he setting of chronic persistent viral infections in human
ubjects. Since a hallmark of HIV-1 infection is CD41
-cell depletion, we asked whether the expected asso-
iation between CD41 and CD81 T-cell responses to
CMV and HIV-1 would be found even in the setting of
chronic HIV-1-induced CD41 T lymphopenia. To answer
this question, we identified a group of 21 HLA-A*02011
individuals and measured both CD41 and CD81 T-cell
responses to CMV. It was previously shown that the CTL
response to CMV is dominated by the response to the
CMV structural protein pp65 (McLaughlin-Taylor et al.,
1994; Wills et al., 1996). It was also shown that most
HLA-A*02011 individuals studied have a dominant re-
sponse to a single pp65 peptide epitope (Wills et al.,
1996). For this reason, we correlated CMV-specific CD41
T-cell responses following stimulation with viral lysates
to CD81 T-cell responses directed at the immunodomi-
nant HLA-A*0201-restricted pp65 epitope.
Cellular immune responses to HIV-1 in a subset of
nine of these subjects were markedly diminished (data
not shown), confirming previous observations in subjects
chronically infected and effectively suppressed with an-
tiretroviral therapy (Autran et al., 1997; Ogg et al., 1999;
Pitcher et al., 1999). In contrast, all 21 individuals studied
had detectable CD41 and CD81 T-cell responses
against CMV antigen. Recently, Zajac et al. (1998) dem-
onstrated that in the setting of CD41 depletion, CD81 T
cells specific for a class I-restricted peptide epitope
(based on tetramer staining) may be functionally si-
lenced, either by deletion or anergy, in an epitope-spe-
cific manner. Here, we observed that the frequency of
CD81 T cells binding to an HLA A2-pp65 tetramer was
strongly associated with the frequency of CD81 T cells
responding functionally to stimulation with the pp65
epitopic peptide. While the absolute numbers (per ml
nfected subjects. (A) CD41 and CD81 T-cell responses to CMV in 21
are illustrated. Solid lines connect CD41 and CD81 T-cell responses
antigens are likely to have lower CD81 T-cell responses to CMV pp65
HIV-1-infected subjects were stratified based on response quartiles.
d ,1.99%; Quartile 3 . 2.00% and ,7.95%; Quartile 4 . 7.96%. CD81
5 NLVPMVATV tetramer) are illustrated for individuals with respect to
t. CD81 T-cell responses are shown as the frequency of A2-pp65
ll responses by CFC and the total number of circulating CD81 cells
unt and measured in cells/ml). Statistical significance was determinedHIV-1-i
tudied
o CMV
y) in 21
.47% an
A2-pp6
artmen
fic T-ce
-cell cotaining within 3 weeks of CD41 CFC assessment; determinations for
(
T
b
total c
U
466 KOMANDURI ET AL.peripheral blood) of functionally reactive cells were al-
ways lower than those of tetramer-binding cells (sug-
gesting that some tetramer-binding cells may be nonre-
sponsive), our data prove that high frequencies of CMV
pp65-responsive cells are both present and responsive,
and therefore likely functional, in most HLA-A*02011
subjects.
These experiments do not directly measure cellular
cytotoxicity of CD81 T cells specific for CMV. It was
previously shown, however, that the frequency of HLA
A2-pp65 tetramer-binding cells in HIV-1-infected sub-
FIG. 4. Associations between CD41 CMV-specific T-cell responses
CD81 T-cell responses to CMV. (A) Association between HLA A2-pp6
CD81 T-cell responses (by the CFC assay using stimulation with pp6
peptide stimulation are expressed as a frequency of CD81 T cells (in %
B) Association between CD41 T-cell responses to CMV (determined
-cell responses to CMV (by the CFC assay following stimulation with p
ased on the lowest quartile vs other CMV-specific CD41 T-cell respo
were adjusted by total circulating CD81 T-cell counts (and measured in
test.jects correlated closely with CD81 cytotoxicity, as mea-
sured by a standard chromium-release assay (Appay etal., 2000). Furthermore, detailed immunophenotypic anal-
yses of a subset of the patients presented here demon-
strated that the A2-pp65 tetramer-binding cells were
CD571perforin1, a phenotype that is closely associated
with cytotoxicity in standard assays (Roederer et al.,
unpublished results).
Several lines of investigation indirectly support the
hypothesis that development and maintenance of a CTL
response in humans is dependent on a sustained anti-
gen-specific CD41 T-cell response (Brodie et al., 1999;
Kalams and Walker, 1998; Riddell and Greenberg, 1995;
C, CD81 T-cell responses by CMV tetramer staining, and functional
MVATV tetramer staining in 21 HIV-1-infected subjects and functional
MVATV peptide). Tetramer staining and functional responses to pp65
istical significance was determined by the Spearman rank correlation.
imulation with CMV antigens in the CFC assay) and functional CD81
VPMVATV peptide). Functional CD81 T-cell responses were stratified
the 21 HLA-A*02011 subjects (as in Fig. 3). CD81 T-cell responses
ells/ml). Statistical significance was determined by the Mann–Whitneyby CF
5 NLVP
5 NLVP
). Stat
after st
p65 NL
nses inRosenberg et al., 1997; Tan et al., 1999). We directly
compared functional CD41 T-cell responses by cytokine
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tion-based quantitation of the antigen-specific CD81 T-
ell response in human subjects. We demonstrated that
ndividuals with weak CD41 T-cell responses to CMV
re unlikely to sustain strong CD81 T-cell responses
measured either by A2-pp65 tetramer staining or by func-
FIG. 5. (A) Diminished CD41 CMV-specific responses are associate
nd CD81 T-cell counts were determined for groups of subjects strati
s in Fig. 3). Statistical significance was determined by the Mann–Whtional examination of CD81 T cells by CFC following
pitopic peptide stimulation with CMV pp65. It should be
hoted that we cannot formally establish a cause-and-
ffect relationship between the loss of CD41 CMV-spe-
ific T-cell responses and an inability to sustain CD81
-cell responses based on these data. This association,
ow firmly established from work in murine models, may
e difficult, if not impossible, to demonstrate in studies of
ower circulating total CD81, but not CD41, T-cell counts. Total CD41
quartile of CD41 CMV-specific T-cell response (with quartile bounds
test.d with luman subjects.
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468 KOMANDURI ET AL.T-cell counts) were also lower in those subjects with
diminished CD41 CMV-specific responses, suggesting
that an inability to maintain CMV-specific CD41 T cells
ight be indicative of more global deficiencies in the
unctional T-cell receptor repertoire. If so, collective de-
lines in aggregate antigen-specific CD81 T-cell re-
ponses might be reflected in the lower total CD81
-cell counts observed in these subjects.
These data suggest that antigen-specific CD41 and
D81 T-cell responses are closely associated even in
he setting of HIV-1-induced CD41 T lymphopenia. In
ontrast to intact CD41 and CD81 T-cell responses
pecific for CMV, T-cell responses to HIV-1 were not
etectable in a subset of the individuals that we studied.
ossibly, the ability to maintain antigen-specific T-cell
esponses to one but not both of these coincident viral
nfections may be related to factors such as differences
n antigenic load between CMV and HIV-1 (leading to
arlier exhaustion of HIV-1-specific T cells) and/or of
ifferential susceptibility to lytic or apoptotic death.
It is notable that diminished CD41 T-cell responses to
MV may occur in association with clinically important
MV disease (Komanduri et al., 1998; Schrier et al.,
995). Our data suggest that such instances are likely to
e associated with a concomitant decline in CD81 T-cell
esponses to CMV. A better understanding of the mech-
nisms underlying this breakdown, as well as those
esponsible for the earlier loss of HIV-1-specific CD41
nd CD81 T-cell responses, may lead to therapeutic
trategies aimed at preserving or augmenting protective
ellular immune responses in AIDS and other immuno-
eficiency states.
MATERIALS AND METHODS
tudy subjects
Thirty-one HIV-1-infected individuals were studied, 13
f whom were evaluated previously for cellular immune
esponses to CMV (Komanduri et al., 1998). Subject 3, a
emale who was a prior injection drug user, was un-
reated at the time of study. The remaining subjects (all
omosexual males) received combination antiretroviral
herapy, generally consisting of at least one protease
nhibitor, as directed by their primary physician. All pa-
ients gave informed consent for the studies, consistent
ith the policies of the institutional review boards at the
niversity of California, San Francisco and the Aaron
iamond AIDS Research Center, New York.
solation of peripheral blood mononuclear cells
PBMC were isolated from heparinized whole blood by
ensity-gradient centrifugation (Life Technologies, Rock-
ille, MD) and washed twice in Dulbecco’s phosphate-
uffered saline (dPBS) prior to use in functional studies,
etramer staining, or viable cryopreservation in 90% FCSSummit Biotechnology, Fort Collins, CO) and 10% DMSO
Sigma, St. Louis, MO).
easurement of CD41 and CD81 T-cell functional
esponses
CMV-specific CD41 T-cell frequencies were charac-
erized as previously described (Komanduri et al., 1998).
riefly, PBMC were stimulated with either CMV lysates or
atched control antigens (Bio-Whittaker, Walkersville,
D) or HIV-1 p24 or gp160 proteins (Protein Sciences,
eridian, CT) for 6 h in the presence of antibody to CD28
1 mg/ml of clone L293, Becton–Dickinson Biosciences,
an Jose, CA) in 96-well microtiter plates (Nunc, Roch-
ster, NY). For CD81 functional studies, PBMC were
timulated with HLA-A*0201-restricted epitopic peptides
f CMV pp65 (residues 495–503: NLVPMVATV) or HIV-1
ag (residues 77–85: SLYNTVATL) at a concentration of
0 mg/ml in the presence of antibody to CD28. The
incubation was done at 37°C in 5% CO2 with the addition
of brefeldin A (Sigma) at a final concentration of 10 mg/ml
for the last 5 h. Following stimulation, cells were washed
in dPBS, incubated for 5 min at 37°C in 0.02% EDTA and
washed in dPBS. Cells were then fixed briefly in 1%
paraformaldehyde (PFA; Sigma), washed in 1% BSA
(Sigma), and frozen for at least 18 h in 1% bovine serum
albumin (BSA) containing 10% DMSO (Sigma). Cells were
then thawed, washed with 1% BSA, sequentially incu-
bated for 10 min in FACSLyse and FACSPerm solutions
(both from Becton–Dickinson Biosciences), and washed
in 1% BSA. Finally, cells were stained with fluoroscein
isothiocyanate (FITC)- or allophycoerythrin (APC)-conju-
gated antibodies against CD4, FITC- or APC-conjugated
antibodies against CD8, peridinin chlorophyll protein
(PerCP)-conjugated antibodies against CD69, and phy-
coerythrin (PE)-conjugated antibodies against TNFa (all
antibodies were obtained from Becton–Dickinson Bio-
sciences except CD4-APC, which was from Exalpha,
Boston, MA). Cells were then fixed in 1% PFA, and col-
lected on a FACSCalibur flow cytometry instrument using
CellQuest software (both Becton–Dickinson Bio-
sciences), as previously described (Komanduri et al.,
1998). Flow cytometry data was analyzed and presented
using Flow Jo software (Tree Star, San Carlos, CA);
100,000 events were analyzed for each sample.
Analysis of CD81 T-cell responses by MHC-tetramer
staining
HLA-A*0201-restricted tetramers were produced using
a method similar to that of Altman et al. (1996) and as
previously described (Callan et al., 1998). Briefly, com-
plexes of HLA class I heavy chains, b2-microglobulin,
and epitopic peptides were biotinylated. The resulting
MHC–peptide complexes were recovered by FPLC puri-
fication and ion-exchange chromatography. Multivalent
complexes were made by incubation with streptavi-
A469CD41/CD81 T-CELL RESPONSES TO CMV IN HIV-1 INFECTIONdin-PE (Sigma) at a molar ratio of 4:1. To determine the
frequency of tetramer-binding CD81 T cells, PBMC (ei-
ther fresh or viably frozen, thawed, and incubated over-
night in RPMI media supplemented with 10% FCS) were
incubated with PE-labeled MHC–tetramer complexes in
dPBS with 0.1% BSA for 20 min at 37°C, followed by an
additional 30 min with FITC anti-CD3 and APC anti-CD8
antibodies (both from Becton–Dickinson Biosciences).
Cells were then fixed in 1% PFA and analyzed on a
FACSCalibur flow cytometer using CellQuest software for
data collection and Flow Jo (Tree Star) for data analysis
and presentation. Consistency of analysis by tetramer
staining was confirmed in a subset of individuals by
staining with HLA A2-pp65 tetramers generated in two
laboratories, with a strong correlation between measure-
ments (R 2 5 0.985, P , 0.0001, data not shown). The
specificity of tetramers was confirmed using HIV-1- or
CMV-specific CTL lines as positive controls; negative
controls included PBMC from an HIV-1-seronegative do-
nor (HIV-1 tetramer) or from an HLA-A*0201- individual
(CMV tetramer) (data not shown).
Statistical analyses
Consistent with our prior observations that CD41
CMV-specific T-cell responses are not normally distrib-
uted in healthy or HIV-1-infected subjects, linear regres-
sion analyses of CD41 and CD81 T-cell responses to
CMV were not informative. Normal ranges for CD41
T-cell responses in CFC assays have not been estab-
lished and might depend on a number of methodological
variables (e.g., stimulation time, permeabilization condi-
tions, the presence or absence of costimulatory antibod-
ies during stimulation). Quartile stratification based on
CD41 T-cell response frequencies was calculated
based on percentile ranks within the overall group using
Microsoft Excel (Microsoft, Redmond, WA). Statistical
significance between groups was determined using the
Mann–Whitney U test and calculated using StatView
(Abacus Concepts, Berkeley, CA).
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